CII
LAB icon

CR Intrinsic Investors’s Standard BioTools LAB Stock Holding History

CR Intrinsic Investors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-240,993
Closed -$4.21M – 373
2013
Q2 		$4.21M Buy
+240,993
New +$4.23M 0.15% 196

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CR Intrinsic Investors's LAB Position: Q3 2013 in Review

CR Intrinsic Investors sold out of Standard BioTools (LAB) in Q3 2013, closing a stake of 240,993 shares — an estimated $4.21M sold.

CR Intrinsic Investors first reported a position in LAB in Q2 2013 and held it in 1 quarter. The position peaked at $4.21M in Q2 2013. 89 funds tracked by Wall St. Rank hold LAB as of Q3 2013.

  • CR Intrinsic Investors reported no remaining Standard BioTools position as of Q3 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 240,993 Standard BioTools shares in Q3 2013, an estimated $4.21M.
  • CR Intrinsic Investors first reported a position in Standard BioTools in Q2 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Standard BioTools position peaked at $4.21M in Q2 2013.
  • 89 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2013.

Based on CR Intrinsic Investors's 13F filing for Q3 2013, filed 14 Nov 2013.